Objective. JDM is associated with multiple potential risk factors for cardiovascular disease, including reduced heart rate variability, systolic/diastolic cardiac dysfunction, abnormal brachial artery reactivity and metabolic syndrome. However, little is known about cardiovascular risk in JDM. We sought to examine the association between JDM and cardiovascular risk factors and disease in US children.
Introduction
JDM is a chronic, autoimmune disorder characterized by inflammation of the skin and muscles. Recent studies estimated the incidence of JDM in the USA at $3.2 per million children annually [1] . Within the paediatric population, JDM is the most common idiopathic inflammatory myopathy. Recognition of the comorbid health conditions associated with JDM in children is essential in order to reduce their morbidity and potentially prevent early mortality. Previous research has focused largely on comorbidities of DM in adults, particularly certain malignancies [24] . However, comorbidities of JDM and their impact on health outcomes remain poorly understood.
Recently, numerous studies have established associations between autoimmune conditions, including DM, and the risk and incidence of cardiovascular disease [5] . JDM is associated with multiple potential factors related to long-term cardiovascular morbidity, including reduced heart rate variability, systolic/diastolic cardiac dysfunction, abnormal brachial artery reactivity and metabolic syndrome [611] . However, while prior studies have demonstrated factors that could confer a higher risk of cardiovascular/cerebrovascular disease in JDM patients, epidemiologic assessment of risk factors and outcomes themselves remains an underexplored area. We hypothesized that children with JDM have increased cardiovascular risk factors and disease even at young ages. We also hypothesized that there are differences of cardiovascular risk related to demographic factors such as age, sex and race/ethnicity. In the present study, we examine the association between JDM and cardiovascular risk factors and disease in a nationwide cohort of children.
Methods
We analysed data from the 200212 National Inpatient Sample (NIS) provided by the Healthcare Cost and Utilization Project (HCUP) from the Agency for Healthcare Research and Quality (AHRQ). Each year of NIS contains an $20% stratified representative sample of all US hospitalizations. Sample weights were created by HCUP that factored the sampling design. These sample weights are needed to provide representative estimates of discharges across the whole country. All data were de-identified and no attempts were made to identify any of the individuals in the database. Patient consent was not obtained as the databases were received de-identified. All parties with access to NIS were compliant to HCUP's formal data use agreement. The study was approved by the Institutional Review Board at Northwestern University.
Identification of JDM and comorbidities JDM and comorbidities were determined through the International Classification of Diseases 9th revision Clinical Modification (ICD-9-CM) diagnostic codes in NIS for each patient discharge (Supplementary Table S1 , available at Rheumatology online). The NIS lists the principal diagnosis, that is, the primary reason for hospitalization, and up to 24 secondary diagnoses. JDM was identified using the ICD-9-CM code 710.3. A previous study validated the use of the discharge diagnosis code 710.3 in the inpatient setting for the study of DM [12] . Patients with ICD-9-CM diagnostic codes of 701.0/710.1 (scleroderma), 710.0 (SLE), 710.4 (PM), 710.8 (MCTD) and 710.9 (UCTD) were excluded to minimize misclassification.
A comorbidity was considered present with either a primary or secondary diagnosis of the disease. Some comorbidities were pre-coded according to AHRQ comorbidity measures and through the NIS Clinical Classification Software (CCS). Comorbidities pre-coded by the AHRQ also utilized Diagnosis-Related Groups and thus would capture a higher frequency of the comorbidities in comparison with use of ICD-9-CM codes alone; therefore, comparing frequencies for comorbidities coded by the AHRQ in comparison with those using only ICD-9-CM codes may not be possible.
Statistics
All data analyses and statistical processes were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Analyses were performed using SURVEY procedures that accounted for the complex strata, clusters and weighting, and allowed for accurate variance estimates. Analyses were limited to patients aged 017 years. RaoScott Chi-square tests were used to identify the demographic associations with JDM. Survey-weighted binary logistic regression models were constructed to determine the association of JDM (independent variable) with various comorbidities (dependent variables). Multivariate models included age (continuous), sex (male/female) and race/ ethnicity (white/black/Hispanic/Asian/multiracial-other) (model 1) as well as obesity, hypertension and diabetes as binary covariates (model 2). Crude and adjusted odds ratios (OR) (95% CIs) and P-values were determined.
Models of association between JDM and comorbidities were also stratified by age (09/1017 years), race/ethnicity (white/black/Hispanic/Asian/multiracial-other) and sex (male/female), while controlling for the other covariates. A two-sided P < 0.05 was considered statistically significant.
Results
Overall, there were 14 535 620 hospital discharges captured in the NIS between the years 2002 and 2012 for children (ages 017 years). There were 909 and 498 admissions with a primary or secondary diagnosis of JDM, which was equivalent to a weighted prevalence of 62.9 and 34.0 per million persons, respectively. Paediatric inpatients with a diagnosis of JDM were 34.6% male, 49.0% white, 18.5% black and 24.1% Hispanic (Table 1) .
Cardiovascular comorbidities of JDM
In bivariate survey logistic regression models, 12 of 13 cardiovascular comorbidities analysed were significantly associated with JDM ( (Table 2) .
Several disorders had no or too infrequent occurrences in children to allow for analysis of association with JDM, including congestive heart failure, diabetes mellitus with chronic complications, atrial fibrillation, peripheral vascular disease, type 2 diabetes, pulmonary hypertension, myocardial infarction, coronary artery disease, heart conduction disorder, cardiomyopathy, supraventricular arrhythmia, cerebrovascular accident, sinoatrial node dysfunction, ventricular tachycardia, history of unspecified circulatory disease, chronic ischaemic heart disease, other cerebrovascular disorders, subendocardial infarction, carotid artery occlusion, chest pain not elsewhere classified and cardiac arrest.
Cardiovascular comorbidities stratified by demographics
To determine which subsets of JDM patients are at highest risk of cardiovascular comorbidities, stratified analyses were performed by demographics for comorbidities that were significant in bivariate analyses and had at least two cases in the JDM and non-JDM group (Fig. 1 
Overlap of comorbidities in JDM
The majority of JDM patients who had peripheral and visceral atherosclerosis, late effects of cerebrovascular disease, personal history of TIA and cerebral infarction without residual deficits, pulmonary circulatory disorders, arrhythmia and bradycardia did not also have obesity, hypertension or diabetes (Table 3) .
In multivariate models that controlled for age, sex and race, as well as obesity, hypertension and diabetes, the associations with JDM remained significant for peripheral and visceral atherosclerosis [4. (Table 2) .
Discussion
The present study found significantly higher odds of numerous cardiovascular and cerebrovascular comorbidities among inpatients with JDM. In particular, JDM was associated with higher odds of cardiovascular risk factors, including obesity, hypertension, diabetes and lipid abnormalities. Furthermore, JDM was associated with peripheral and visceral atherosclerosis, history of TIA and cerebral infarction, late effects of cerebrovascular disease, pulmonary circulatory disorder, arrhythmia and bradycardia even in the absence of obesity, hypertension and diabetes. There were age, racial/ethnic and sex predilections for some comorbidities. Most of the cardiovascular and cerebrovascular comorbidities in JDM occurred in adolescents. However, obesity, hypertension, arrhythmia and bradycardia were significantly increased in children age 09 years. Hypertension was most common in Asians, followed by Hispanics, whites and blacks. Obesity occurred more commonly in white and Hispanic children with JDM. Diabetes, late effects of cerebrovascular disease and personal history of TIA and cerebral infarction were more common in black children. Pulmonary circulatory disorder was more common in Hispanic children. There were apparent sex differences, where female but not male children had higher odds of obesity, hypertension, arrhythmia, bradycardia, pulmonary circulatory disorders, late effects of cerebrovascular disease and personal history of TIA and cerebral infarction. Together, the present study suggests that children with JDM have higher odds of cardiovascular/cerebrovascular comorbidities, with adolescents, girls and racial/ethnic minorities being at highest risk.
The observed associations between JDM and cardiovascular/cerebrovascular risk factors and comorbidities corroborate the findings of previous smaller studies [69] . A study of 17 children with myositis (of whom 16 had JDM) from the National Institutes of Health Clinical Centre found that a high proportion had elevated BMI percentile, elevated blood pressure, high fasting insulin levels and triglycerides, insulin resistance and cholesterol abnormalities, and frequently met criteria for metabolic syndrome [6] . Another study evaluated eight adults with and eight without a history of JDM and found that adults with a history of JDM had higher carotid intimal thickness and that their brachial artery reactivity suggested impairment of endothelial function despite being younger and having lower BMI [8] . Multiple studies have shown higher rates of systolic and diastolic cardiac dysfunction, which correlated with duration and severity of muscle and skin disease [911] . Finally, a British Colombian study including 350 adults with DM and 10:1 matched adults from the general population found significantly higher risk of myocardial infarction. It is possible that children with JDM may face similar risks in adulthood [13] .
In the present study, cardiovascular risk factors were already increased in younger children, whereas cardiovascular and cerebrovascular disease occurred more often in adolescents. However, adolescents with cardiovascular disease did not also have higher rates of cardiovascular risk factors. This suggests that traditional cardiovascular risk factors may not adequately explain rates of cardiovascular/cerebrovascular comorbidities in children and adolescents with JDM. Children with other paediatric rheumatic conditions, such as SLE, have been found to have accelerated atherosclerosis, with some non-traditional risk factors such as chronic inflammation, vitamin D status and steroid use potentially explaining this finding [1419] . In regards to the role of chronic inflammation, previous studies have demonstrated elevated levels of TNF-a in muscle fibres of children with JDM [20] . TNF-a polymorphisms are thought to be associated with specific disease features (e.g. dystrophic calcifications in JDM) [21] and are known to contribute to cardiovascular/cerebrovascular disease in other populations [22, 23] . While the inflammatory milieu may lead to elevated cardiovascular risk in JDM, the use of intravenous and oral corticosteroids and other immunosuppressive agents could also affect rates of cardiovascular comorbidity, as has been demonstrated in paediatric lupus [1719] .
In addition to chronic inflammation, there may be other non-traditional cardiovascular risk factors that increase the long-term cardiovascular/cerebrovascular risks in children with JDM. Many inflammatory diseases are associated with endothelial dysfunction and JDM in particular is known to cause severe vasculopathy affecting the microcirculation as well as larger vessels (i.e. abnormal brachial artery reactivity) [6, 24, 25] . However, the specific harmful or helpful effects of various systemic inflammatory molecules, for example, cytokines and chemokines, remain unknown. Lipodystrophy, which is likely underrecognized in clinical practice but shows a strong association with JDM in our study and prior literature, is itself associated with higher rates of insulin resistance and hypertriglyceridaemia [2629] . Some studies of adults with PM/DM demonstrate subclinical myocardial inflammation, which can progress to fibrosis. This could conceivably elevate risks of cardiovascular disease if these features are present in JDM patients [9, 3034] . Physical inactivity is a well-established risk factor for cardiovascular disease and children with JDM, who often exhibit ongoing deconditioning even after disease remission, may be at even higher risk than other children with rheumatic diseases in whom high rates of physical inactivity have been documented [3539] . Aside from the observed associations, there are likely multiple additional factors that we were unable to analyse, such as cumulative exposure to systemic corticosteroids, physical inactivity and the effects of chronic disease. Future studies are needed to distinguish between the complex associations in JDM.
Previous epidemiological studies have demonstrated higher incidence of JDM in girls [40] . The present study suggests that females with JDM are also at higher risk for cardiovascular and cerebrovascular disease. Females were more often impacted by obesity, hypertension, arrhythmia, bradycardia, pulmonary circulatory disorders, late effects of cerebrovascular disease, personal history of TIA and cerebral infarction. There were also intriguing racial/ethnic differences of cardiovascular and cerebrovascular comorbidities. Black children with JDM were preferentially impacted by diabetes, late effects of cerebrovascular disease and personal history of TIA and cerebral infarction; Hispanic JDM patients were more often affected by pulmonary circulatory disorders; and Asians had the highest rates of hypertension. In contrast, the incidence of JDM was highest in whites [40] . The reasons for these sex and racial/ethnic differences are unclear but could be related to gender/racial differences in the relationships between adiposity and inflammation, gender/ racial differences in health behaviours (e.g. diet, physical activity) and underlying health disparities by race and/or socioeconomic status, including social differences, economics, level of education and access to medical and/or specialty care [22, 4145] . Further study is warranted on gender and racial/ethnic differences in cardiovascular and cerebrovascular comorbidities in JDM. Strengths of this study include an analysis of a nationally representative sample of all hospitalizations over a period of 11 years with over 14 million records and 1407 cases of JDM. We previously validated the use of ICD-9-CM codes for identifying DM in the inpatient setting [12] . We attempted to minimize misclassification error by excluding PM, SLE, MCTD, UCTD and scleroderma. Study limitations include the retrospective nature of the study and inability to distinguish between different subsets of JDM, such as hypomyopathic/amyopathic DM. We were unable to determine how many of the hospitalizations were due to readmissions or transfers between hospitals. We could not verify the methods by which some comorbidities were designated (e.g. atherosclerosis) or which exact diagnoses a patient had when certain generic codes were applied (e.g. pulmonary circulatory disorder). Despite the large sample size overall, there were low frequencies of children with JDM and some less common comorbidities, precluding in-depth analysis; subanalyses by age, race/ethnicity and sex should be considered exploratory given the limited statistical power. Future studies are needed to examine those disorders. The patients analysed are from an inpatient setting, which may not be generalizable to all children with JDM. It is likely that children admitted primarily for JDM have more severe disease, have received more intensive treatment and do not represent the entire spectrum of JDM. The dates of diagnosis of JDM and comorbidities were not available in the NIS, precluding assessment of temporal relationships between JDM and comorbidities. We were unable to control for the treatments of JDM and their effects on comorbidities, as treatment data are not available in the NIS. Systemic corticosteroids and immunosuppressants could affect the observed frequencies of these comorbidities. Finally, adults with JDM were not assessed in this study since onset dates were not available in the NIS. Future studies are needed to determine cardiovascular risk in adults with a past and/or current history of JDM.
In conclusion, JDM is associated with higher odds of cardiovascular risk factors, including obesity, hypertension, diabetes and lipid abnormalities, even in young children. Moreover, JDM was associated with higher odds of cardiovascular and cerebrovascular disease in adolescents, including atherosclerosis, TIA and cerebral infarction. These comorbidities occurred in adolescents who did not also have cardiovascular risk factors, suggesting a role for non-traditional risk factors including chronic inflammation, treatment side-effects, vasculopathy, lipodystrophy, subclinical myocarditis and physical inactivity. Girls and specific racial/ethnic groups had higher odds of these comorbidities. Future research is needed to confirm these findings and identify strategies to reduce cardiovascular risk in children with JDM.
